{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/14/3311435/0/en/Legend-Biotech-Establishes-Clinical-Proof-of-Concept-for-LB2501-a-Potential-First-in-Class-In-Vivo-CD19-CD20-Dual-Targeting-CAR-T-in-Relapsed-Refractory-B-Cell-Non-Hodgkin-Lymphoma.html", "message": "News view counter 798416 successfully enlarged"}